<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699515</url>
  </required_header>
  <id_info>
    <org_study_id>200647-0008</org_study_id>
    <nct_id>NCT02699515</nct_id>
  </id_info>
  <brief_title>MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is assess the safety and tolerability of MSB0011359C. Study&#xD;
      consists of dose-escalation part and an expansion part in subjects with metastatic or locally&#xD;
      advanced solid tumors, for which no standard effective therapy exists or a standard therapy&#xD;
      has failed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 11, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with DLT (Dose limiting Toxicity): dose escalation part</measure>
    <time_frame>Baseline up to Week 3</time_frame>
    <description>A DLT is defined as any grade greater than or equal to (&gt;=) 3 adverse event suspected to be related to investigational medicinal product (IMP) by the Investigator and / or Sponsor occurring in the DLT evaluation period confirmed by the Safety Monitoring Committee (SMC) to be relevant for the IMP treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>First trial drug administration up to 30 days after the last drug administration assessed up to 2 years</time_frame>
    <description>An Adverse Event (AE) is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A Serious Adverse Event (SAE) is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. AEs (SAEs and non-SAEs) will be considered TEAEs when emerging on treatment period defined as the time from the first trial drug administration up to 30 days after the last drug administration date or the earliest date of subsequent anticancer drug therapy minus 1 day, whichever occurs first, unless otherwise stated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with treatment-related Adverse Events (AE)</measure>
    <time_frame>First trial drug administration up to 30 days after the last drug administration assessed up to 2 years</time_frame>
    <description>Treatment related AEs are any untoward medical occurrence in a subject who received study drug with causal relationship with the investigational product as assessed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of MSB0011359C</measure>
    <time_frame>Pre-dose, 0, 4 hour post dose on Day 1, 2,8,15,29,43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum concentration (Cmin) of MSB0011359C</measure>
    <time_frame>Pre-dose, 0, 4 hour post dose on Day 1, 2,8,15,29,43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve from zero to last sampling time (AUC0-t) of MSB0011359C</measure>
    <time_frame>Pre-dose, 0, 4 hour post dose on Day 1, 2,8,15,29,43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve from time zero to infinity (AUC0-inf) of MSB0011359C</measure>
    <time_frame>Pre-dose, 0, 4 hour post dose on Day 1, 2,8,15,29,43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life (t1/2) of MSB0011359C</measure>
    <time_frame>Pre-dose, 0, 4 hour post dose on Day 1, 2,8,15,29,43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum titers of anti-MSB0011359C antibodies</measure>
    <time_frame>Predose, Day 15, 43, 85 and every 6-weekly until progression or end of the treatment whichever occur first, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) as assessed by investigator: Dose escalation part</measure>
    <time_frame>Date of randomization up to 2 years</time_frame>
    <description>BOR will be assessed by investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. BOR is defined as sum of complete response and partial response (CR+PR). For target lesions (TLs), CR was defined as the disappearance of all TLs; PR was defined as at least a 30 percent (%) decrease in the sum of largest diameter (SLD) of the TLs, taking as a reference the baseline SLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) as assessed by investigator: Expansion part</measure>
    <time_frame>Date of randomization up to 2 years</time_frame>
    <description>BOR will be assessed by investigator according to RECIST Version 1.1. BOR is defined as sum of CR and PR. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30 percent (%) decrease in the SLD of the TLs, taking as a reference the baseline SLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) as assessed by Independent Endpoint Review Committee (IRC): Expansion part</measure>
    <time_frame>Date of randomization up to 2 years</time_frame>
    <description>The BOR per Independent Endpoint Review Committee (IRC) adjudication will be determined according to RECIST 1.1. BOR is defined as sum of CR and PR. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30 percent (%) decrease in the SLD of the TLs, taking as a reference the baseline SLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Date of randomization up to 2 years</time_frame>
    <description>Time from first assessment of CR to disease progression or death, for TLs, CR was defined as the disappearance of all TLs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Date of randomization up to 2 years</time_frame>
    <description>The disease control rate is defined as the percentage of subjects with BOR. The BOR per IRC adjudication will be determined according to RECIST 1.1. BOR is defined as sum of CR and PR. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free survival (PFS) time</measure>
    <time_frame>Date of randomization until death or progressive disease assessed up to 2 years</time_frame>
    <description>PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PFS will be assessed as RECIST v1.1 as adjudicated by IRC. PD is defined as at least a 20 % increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) time</measure>
    <time_frame>Date of randomization until death assessed up to 2 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MSB0011359C (M7824)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSB0011359C</intervention_name>
    <description>Subjects with metastatic or locally advanced solid tumors will receive intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.</description>
    <arm_group_label>MSB0011359C (M7824)</arm_group_label>
    <other_name>M7824</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to give written informed consent and has signed the appropriate&#xD;
             written informed consent form (ICF), prior to performance of any trial activities&#xD;
&#xD;
          -  Eligible male and female subjects aged greater than or equal to (&gt;=)20 years&#xD;
&#xD;
          -  Histologically or cytologically proven metastatic or locally advanced solid tumors,&#xD;
             for which no effective standard therapy exists or standard therapy has failed&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG) performance status of 0&#xD;
             to 1 at trial entry&#xD;
&#xD;
          -  Life expectancy &gt;=12 weeks as judged by the Investigator.&#xD;
&#xD;
          -  Adequate hematological function defined by white blood cell (WBC) count &gt;=3*10^9/Liter&#xD;
             with absolute neutrophil count (ANC) &gt;=1.5*10^9/Liter, lymphocyte count &gt;=0.5*&#xD;
             10^9/Liter, platelet count &gt;=75*10^9/Liter, and Hemoglobin (Hgb) &gt;= 9 grams per&#xD;
             deciliter (g/dL) (in absence of blood transfusion).&#xD;
&#xD;
          -  Adequate hepatic function defined by a total bilirubin level &lt;=1.5 × Upper limit of&#xD;
             normal (ULN), an AST level &lt;= 2.5 × ULN, and an ALT level &lt;= 2.5 × ULN.&#xD;
&#xD;
          -  Adequate renal function defined by an estimated creatinine clearance &gt;50 milliliter&#xD;
             per minute (mL/min) according to the Cockcroft-Gault formula or by measure of&#xD;
             creatinine clearance from 24 hour urine collection.&#xD;
&#xD;
        Other protocol-defined exclusion criteria could apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent treatment with non-permitted drugs and other interventions&#xD;
&#xD;
          -  Anticancer treatment within 28 days before the start of trial treatment, for example&#xD;
             cyto reductive therapy, radiotherapy (with the exception of palliative bone directed&#xD;
             radiotherapy), immune therapy, or cytokine therapy&#xD;
&#xD;
          -  Major surgery within 28 days before the start of trial treatment (excluding prior&#xD;
             diagnostic biopsy)&#xD;
&#xD;
          -  Systemic therapy with immunosuppressive agents within 7 days before the start of trial&#xD;
             treatment; or use of any investigational drug within 28 days before the start of trial&#xD;
             treatment&#xD;
&#xD;
          -  Previous malignant disease other than the target malignancy to be investigated in this&#xD;
             trial with the exception of cervical carcinoma in situ and superficial or non invasive&#xD;
             bladder cancer (treated with curative intent) within the last 5 years or basal cell or&#xD;
             squamous cell carcinoma in situ within the last 3 years&#xD;
&#xD;
          -  Rapidly progressive disease which, in the opinion of the Investigator, may predispose&#xD;
             to inability to tolerate treatment or trial procedures&#xD;
&#xD;
          -  Active or history of central nervous system metastases, except as in the&#xD;
             melanoma-specific Central nervous system (CNS) criteria listed above&#xD;
&#xD;
          -  Receipt of any organ transplantation, including allogeneic stem-cell transplantation,&#xD;
             but with the exception of transplants that do not require immunosuppression (eg,&#xD;
             corneal transplant, hair transplant)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NHO Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center East, Department of Experimental Therapeutics</name>
      <address>
        <city>Kashiwa</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center East, Department of hepatobiliary and pancreatic oncology</name>
      <address>
        <city>Kashiwa</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kitaadachi-gun</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University Hospital</name>
      <address>
        <city>Osakasayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center, Department of Experimental Therapeutics</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center, Department of hepatobiliary and pancreatic oncology</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center, Department of Gastroenterology</name>
      <address>
        <city>Yokohama</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center, Department of Gastrointestinal Surgery</name>
      <address>
        <city>Yokohama</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital; Linkou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.intrapidclinicaltrials.com</url>
    <description>INTR@PID Clinical Trial Program</description>
  </link>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=200647-0008</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MSB0011359C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

